Andrew M. Green became a director of the Company on July 26, 2006, upon

the merger with JDA. On June 25, 2007, he was appointed as Chief Executive

Officer and President. He had been a consultant to JDA from May 2006 until the

merger. Previously, since June 2005, he was a principal in NeoMedica, LLC, a

consulting group that specialized in executive level medical device consulting

for clients that included early stage ventures dealing with Class III devices

involving cardiology, ophthalmology, orthopedics, and electrophysiology. Prior

to that, from 1996 until 2005, he was employed by the Novoste Corporation (a

publicly traded medical device company). His final position with Novoste was as

a corporate officer with responsibility for Regulatory Affairs, Clinical

Affairs, Quality Assurance and New Technology/Business Development. From 1993

until his employment with Novoste, he was employed as a Scientific

Reviewer/Biomedical Engineer for the FDA, where he was responsible for the

review of scientific, technical, pre-clinical and clinical data submitted in

support of the safety and effectiveness of both interventional and general

cardiovascular devices. He holds a BS degree in Biological Sciences and an MS

degree in Bioengineering, both from Clemson University, where his research

focused on characterization and use of materials in a biological environment.